We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candida... Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Show more
Ask ADVFN Intelligence (AI)
LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.73 | -6.06312292359 | 12.04 | 12.56 | 11.04 | 1150997 | 11.57974506 | CS |
| 4 | -4.59 | -28.8679245283 | 15.9 | 16.5243 | 9.775 | 2305003 | 11.5721198 | CS |
| 12 | -55.91 | -83.1746504017 | 67.22 | 72.37 | 9.775 | 1556020 | 20.60151738 | CS |
| 26 | -40.59 | -78.2080924855 | 51.9 | 72.37 | 9.775 | 867278 | 28.02743462 | CS |
| 52 | -44.99 | -79.9111900533 | 56.3 | 73 | 9.775 | 611972 | 36.00972115 | CS |
| 156 | -30.31 | -72.8255646324 | 41.62 | 73 | 9.775 | 356647 | 38.51053074 | CS |
| 260 | -8.79 | -43.7313432836 | 20.1 | 88.8 | 9.775 | 274801 | 40.97732065 | CS |
| Symbol | Price | Vol. |
|---|---|---|
| TCTMTCTM Kids IT Education Inc | US$ 0.764 (321.87%) | 729.72M |
| NVDANVIDIA Corporation | US$ 120.07 (-3.67%) | 388.54M |
| RIMEAlgorhythm Holdings Inc | US$ 0.02565 (5.12%) | 338.75M |
| BHATBlue Hat Interactive Entertainment Technology | US$ 0.0355 (-11.25%) | 236.29M |
| CLEUChina Liberal Education Holdings Ltd | US$ 0.1938 (30.77%) | 234.8M |
TheFinalCD
3 weeks ago
retireat40
1 month ago
retireat40
2 months ago
Dennis14
2 months ago
Monksdream
5 months ago
Monksdream
11 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
